Skip to content
Screener

Glaukos GKOS Common Stock

Common Stock at other companies

Johnson & Johnson logo
Johnson & JohnsonJNJ
$3.12B
Sight Sciences, Inc. logo
Sight Sciences, Inc.SGHT
$55K+5.8%
AbbVie logo
AbbVieABBV
$18M0.0%
Schering-Plough logo
Schering-PloughSGP
154.4M0.0%
Bausch + Lomb logo
Bausch + LombBLCO
$0
Ocular Therapeutix logo
Ocular TherapeutixOCUL
$22K+37.5%

Other financials

Income statement

See full
Revenue$185.6M+49.5%
Gross profit$151.6M+55.9%
Operating income-$17.3M+23.9%
Net income-$18.4M+6.5%
EPS (diluted)-$0.31+8.8%

Balance sheet

See full
Cash & equivalents$114.5M+13.6%
Total debt$105.9M-1.4%
Total equity$682.5M-10.8%
Total assets$920.5M-6.7%

Cash flow

See full
Operating cash flow$14.8M
CapEx$2.7M+132%
Free cash flow-$16.5M+19.4%

Valuation

See full
Market cap$10.09B+98.7%
Enterprise value$10.08B+98.3%
P/S16.5×+4.7×

Profitability

See full
Gross margin61%-15.4pp
Operating margin-31.6%+22.2pp
Net margin-30.7%+23.3pp
FCF margin-13.2%-3.9pp

Returns & leverage

See full
Return on equity-26%-11,301pp
Debt / equity0.2×0.0×
Current ratio-0.5×

Where this comes from

Reported directly by Glaukos in its filing.

Tagged under the XBRL concept us-gaap:CommonStockValue.

The source filing: Glaukos’s 10-Q, filed July 29, 2026.

Filed
Jul 29, 2026, 5:06 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-324201
Line itemJune 30, 2026December 31, 2025
Commitments and contingencies (Note 11)
Stockholders' equity:
Preferred stock, $0.001 par value; 5,000 shares authorized; no shares issued and outstanding as of June 30, 2026 and December 31, 2025--
Common stock, $0.001 par value; 150,000 shares authorized; 58,886 and 57,539 shares issued and 58,858 and 57,511 shares outstanding as of June 30, 2026 and December 31, 2025, respectively5958
Additional paid-in capital1,651,4651,586,056
Accumulated other comprehensive income2,3843,303
Accumulated deficit(971,290)(933,130)
Less treasury stock (28 shares as of June 30, 2026 and December 31, 2025)(132)(132)

Item 1. Financial Statements

FAQ

What is Glaukos's common stock?
Glaukos (GKOS) reported common stock of $59K in Q2 2026.
How has Glaukos's common stock changed year-over-year?
Glaukos's common stock increased by 3.5% year-over-year, from $57K to $59K.
What is the long-term trend for Glaukos's common stock?
Over 5 years (2020 to 2025), Glaukos's common stock has grown at a 5.2% compound annual growth rate (CAGR), from $45K to $58K.
What does common stock mean?
The par value of all common shares issued and outstanding, typically a nominal amount ($0.01 or $0.001 per share).

Ask your AI about Glaukos's common stock.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude